Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme

Published:2012-09-09 Issue:1 Volume:15 Page:42-54
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Niswender K.¹,Pi-Sunyer X.²,Buse J.³,Jensen K. H.⁴,Toft A. D.⁵,Russell-Jones D.⁶,Zinman B.⁷

Affiliation:

1. Division of Diabetes, Endocrinology and Metabolism, Department of Medicine; Vanderbilt University School of Medicine; Nashville; TN; USA

2. Division of Endocrinology Diabetes and Nutrition, St Luke's-Roosevelt Hospital, Columbia University; New York; NY; USA

3. Diabetes Care Center; University of North Carolina School of Medicine; Chapel Hill; NC; USA

4. Novo Nordisk A/S; Bagsvaerd; Denmark

5. Novo Nordisk Pharma Ltd; Crawley; West Sussex; UK

6. Department of Diabetes and Endocrinology, Royal Surrey County Hospital, University of Surrey; Guildford; Surrey; UK

7. Samuel Lunenfeld Research Institute; Mount Sinai Hospital, University of Toronto; Toronto; ON; Canada

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2012.01673.x/fullpdf

Reference37 articles.

1. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies;Klein;Diabetes Care,2004

2. Mortality in people with Type 2 diabetes in the UK;Mulnier;Diabet Med,2006

3. Increasing BMI and waist circumference and prevalence of obesity among adults with Type 2 diabetes: the National Health and Nutrition Examination Surveys;Kramer;J Diabetes Complications,2010

4. Bodyweight changes associated with antihyperglycemic agents in type 2 diabetes mellitus;Hermansen;Drug Saf,2007

5. Bariatric surgery: an IDF statement for obese type 2 diabetes on behalf of the International Diabetes Federation Taskforce on Epidemiology and Prevention;Dixon;Diabet Med,2011

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis;Diabetes, Metabolic Syndrome and Obesity;2023-11

2. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study;Diabetologia;2023-07-28

3. Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme;Diabetes, Obesity and Metabolism;2023-05-29

4. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials;The Lancet Diabetes & Endocrinology;2023-01

5. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron ( PF ‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus;Diabetes, Obesity and Metabolism;2022-12-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3